Background: Currently available combination antiretroviral therapy (cART) can successfully control HIV replication. However, conventional treatment lacks the ability to clear the latent reservoir and stop viral production, which remains the major obstacle in achieving a cure. Novel strategies are required to permanently disrupt the HIV genome in the latently infected cells. In this study we have investigated the potential of the CRISPR-Cas9 RNA guided DNA endonucleases system to edit the HIV genome, prevent re-activation from latently infected cells and halt new infections.
Methods: The CRISPR-Cas9 system is comprised of a Cas9 protein, which in combination with a guideRNA (gRNA), is able to cleave a complementary dsDNA sequence. gRNAs were designed to target HIV LTR, protease (PR), reverse transcriptase (RT), integrase (IN) and the structural matrix protein (MA). gRNAs against human B2M, HLA and CD45 were used as controls. The CRISPR-Cas9 system was cloned in a lentivirus vector and used to transduce SupT1 and Jurkat cells. The latter is latently infected with near full-length HIV and expresses GFP upon TNFα stimulation (J.Lat Full Length Clone 15.4). SupT1 cells are transduced with the lentiviral constructs and subsequently infected with HIV using three different MOIs and viral replication was monitored by HIV DNA quantification and HIV CA-p24 production. On and off targeting efficiency (three genes per CRISPR) of the different CRISPRs was assessed by deep sequence analysis.
Results: Lentiviral transduction in SupT1 and Jurkat cells resulted in stable expression of the CRISPR-Cas9 system. Deep sequence analysis demonstrated efficient HIV genome editing (75-99%) and an off-target efficiency ranging between 1.7-0.4%. TNFα –induced HIV reactivation from latently infected T cells was significantly reduced after transduction with CRISPRs specifically targeting the LTR (empty vector 48±2.98% GFP+ cells vs LTR-6 15±6.63% and LTR-4 26± 2.76% GFP+ cells; p<0.05). Subsequently, we investigated the potential of CRISPRS targeting the LTR, PR, RT, IN and MA to inhibit viral replication. HIV DNA quantification demonstrated up to 40-fold reduction in intracellular HIV DNA and a significant reduction in virus production ranging from 91-99% inhibition (p <0.05).
Conclusions: The newly discovered CRISPR-Cas9 system is able to target HIV efficiently in both primary infection and latency models and may provide a specific, efficacious prophylactic and therapeutic anti-viral approach.